Wednesday, July 8, 2026

Patent intelligence · US

US 11918560

Serine protease inhibitor for treating coronavirus infection

granted A61KA61K31/435A61K31/4409A61K31/495
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 18
Applicant portfolio 40
Patent details — US 11918560
Jurisdiction
US
Status
granted
Grant date
Mar 5, 2024
Expiration
Feb 29, 2044
Claims
20
CPC classes
A61K, A61K31/435, A61K31/4409, A61K31/495
View on Google Patents ↗

Quick answer

US 11918560 (Serine protease inhibitor for treating coronavirus infection) is held by RedHill Biopharma Ltd.. Status: granted. Granted Mar 5, 2024. Expires Feb 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/435, A61K31/4409, A61K31/495, A61K9/0053, A61K9/48

More from RedHill Biopharma Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12370206

    Therapy for inhibition of single-stranded RNA virus replication

    RedHill Biopharma Ltd. · Expires Jul 24, 2045

    granted
  2. US 12115150

    Biomarkers of coronavirus pneumonia

    RedHill Biopharma Ltd. · Expires Oct 10, 2044

    granted
  3. US 11931463

    All-in-one fixed-dose combination for treating Helicobacter pylori infection

    RedHill Biopharma Ltd. · Expires Mar 14, 2044

    granted
  4. US 11878011

    Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

    RedHill Biopharma Ltd. · Expires Jan 18, 2044

    granted
  5. US 11786541

    Inhibitor of sphingosine kinase 2 for treating Ebola

    RedHill Biopharma Ltd. · Expires Oct 12, 2043

    granted
  6. US 11633385

    Combination compositions for treatment of cancer

    RedHill Biopharma Ltd. · Expires Apr 20, 2043

    granted
  7. US 11590154

    Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

    RedHill Biopharma Ltd. · Expires Feb 23, 2043

    granted

Frequently asked questions

What is US patent 11918560?

US 11918560 (Serine protease inhibitor for treating coronavirus infection) is held by RedHill Biopharma Ltd.. Status: granted. Granted Mar 5, 2024. Expires Feb 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11918560?

RedHill Biopharma Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.

When does US 11918560 expire?

Our index shows an expiration date of Feb 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.